Dynasty Wealth Management LLC Acquires 22 Shares of argenx SE (NASDAQ:ARGX)

Dynasty Wealth Management LLC boosted its holdings in argenx SE (NASDAQ:ARGX) by 3.4% during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 677 shares of the company’s stock after acquiring an additional 22 shares during the quarter. Dynasty Wealth Management LLC’s holdings in argenx were worth $416,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. SG Americas Securities LLC increased its stake in argenx by 6.2% in the fourth quarter. SG Americas Securities LLC now owns 358 shares of the company’s stock valued at $220,000 after acquiring an additional 21 shares during the last quarter. Choreo LLC grew its position in argenx by 4.4% during the fourth quarter. Choreo LLC now owns 551 shares of the company’s stock valued at $342,000 after acquiring an additional 23 shares during the last quarter. IFP Advisors Inc grew its position in argenx by 4.2% during the fourth quarter. IFP Advisors Inc now owns 641 shares of the company’s stock valued at $394,000 after acquiring an additional 26 shares during the last quarter. Raymond James Trust N.A. grew its holdings in shares of argenx by 6.0% during the 3rd quarter. Raymond James Trust N.A. now owns 495 shares of the company’s stock valued at $268,000 after purchasing an additional 28 shares during the last quarter. Finally, Financial Perspectives Inc grew its holdings in shares of argenx by 39.4% during the 4th quarter. Financial Perspectives Inc now owns 145 shares of the company’s stock valued at $89,000 after purchasing an additional 41 shares during the last quarter. Hedge funds and other institutional investors own 60.32% of the company’s stock.

Wall Street Analyst Weigh In

ARGX has been the topic of a number of analyst reports. JMP Securities lifted their target price on shares of argenx from $606.00 to $696.00 and gave the stock a “market outperform” rating in a research report on Tuesday, January 14th. Wedbush reiterated an “outperform” rating and issued a $655.00 price objective on shares of argenx in a report on Tuesday, December 3rd. Scotiabank raised argenx from a “sector perform” rating to a “sector outperform” rating and lifted their price target for the stock from $439.00 to $715.00 in a research note on Tuesday, November 5th. Deutsche Bank Aktiengesellschaft downgraded shares of argenx from a “hold” rating to a “sell” rating in a research note on Friday, January 17th. Finally, Truist Financial reaffirmed a “buy” rating and issued a $700.00 target price (up from $660.00) on shares of argenx in a research note on Tuesday, January 14th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, eighteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $661.17.

argenx Stock Down 0.0 %

argenx stock opened at $624.67 on Friday. The company has a market capitalization of $37.96 billion, a P/E ratio of -709.85 and a beta of 0.58. The stock’s 50 day moving average is $642.61 and its 200 day moving average is $589.72. argenx SE has a twelve month low of $349.86 and a twelve month high of $678.21.

argenx (NASDAQ:ARGX) last released its earnings results on Thursday, February 27th. The company reported $1.58 EPS for the quarter, topping analysts’ consensus estimates of $0.98 by $0.60. argenx had a negative return on equity of 1.45% and a negative net margin of 2.11%. The firm had revenue of $761.22 million for the quarter, compared to analysts’ expectations of $678.52 million. As a group, equities analysts expect that argenx SE will post 3.13 EPS for the current year.

argenx Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.